Analysts Offer Predictions for Myriad Genetics Q1 Earnings

Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) - Research analysts at Leerink Partnrs dropped their Q1 2025 EPS estimates for shares of Myriad Genetics in a report issued on Monday, December 9th. Leerink Partnrs analyst P. Souda now expects that the company will post earnings per share of ($0.07) for the quarter, down from their prior estimate of ($0.05). Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Myriad Genetics' current full-year earnings is ($0.32) per share. Leerink Partnrs also issued estimates for Myriad Genetics' Q2 2025 earnings at ($0.04) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.18) EPS.

Several other research firms also recently issued reports on MYGN. Wells Fargo & Company began coverage on Myriad Genetics in a research note on Tuesday, August 27th. They set an "overweight" rating and a $35.00 price target for the company. Leerink Partners downgraded shares of Myriad Genetics from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $30.00 to $21.00 in a report on Monday. Morgan Stanley cut their price objective on Myriad Genetics from $32.00 to $21.00 and set an "equal weight" rating for the company in a research report on Monday, November 18th. Scotiabank increased their target price on Myriad Genetics from $29.00 to $34.00 and gave the company a "sector outperform" rating in a report on Tuesday, August 13th. Finally, Piper Sandler reduced their price objective on Myriad Genetics from $30.00 to $24.00 and set a "neutral" rating on the stock in a research report on Monday, November 11th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $25.42.

Myriad Genetics Price Performance

MYGN stock traded down $0.83 during midday trading on Wednesday, hitting $14.51. 964,862 shares of the stock were exchanged, compared to its average volume of 747,166. The stock's 50-day moving average price is $19.55 and its 200-day moving average price is $23.76. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -11.48 and a beta of 1.87. Myriad Genetics has a fifty-two week low of $14.34 and a fifty-two week high of $29.30.

Insiders Place Their Bets

In other news, CEO Paul J. Diaz sold 15,000 shares of the stock in a transaction on Friday, October 11th. The shares were sold at an average price of $22.93, for a total value of $343,950.00. Following the completion of the sale, the chief executive officer now owns 962,378 shares of the company's stock, valued at $22,067,327.54. This represents a 1.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Myriad Genetics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 Hong Kong Ltd purchased a new stake in shares of Myriad Genetics during the third quarter valued at approximately $32,000. Innealta Capital LLC acquired a new stake in Myriad Genetics during the 2nd quarter valued at $36,000. GAMMA Investing LLC increased its stake in Myriad Genetics by 34.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,620 shares of the company's stock worth $44,000 after buying an additional 412 shares during the period. Point72 DIFC Ltd acquired a new position in Myriad Genetics in the 2nd quarter worth $60,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Myriad Genetics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company's stock valued at $87,000 after buying an additional 583 shares during the last quarter. 99.02% of the stock is owned by institutional investors and hedge funds.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.